Open Access<p>Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer</p>
Author(s) -
Susumu Noguchi,
Keiichiro Suminaga,
Takahiro Kaki,
Hiroaki Kawachi,
Akari Fukao,
Satoshi Terashita,
Sadao Horikawa,
Tatsuyoshi Ikeue,
Takakazu Sugita
Publication year - 2020
Publication title -
lung cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.433
H-Index - 16
ISSN - 1179-2728
DOI - 10.2147/lctt.s254146
Subject(s) - pembrolizumab , medicine , lung cancer , adverse effect , oncology , rash , cancer , nivolumab , immunotherapy
The effects of immune checkpoint inhibitors have been reported to be linked with immune-related adverse events (irAEs). In patients with advanced non-small-cell lung cancer, who tested positive for programmed death-ligand 1 (PD-L1), pembrolizumab, an immune checkpoint inhibitor can be used as a treatment, and it was found to improve overall survival. However, there are only a few reports on the relationship between the therapeutic effects of pembrolizumab in patients with lung cancer and the irAEs of pembrolizumab. The purpose of this study was to determine the correlation between immune-related adverse events and the effects of pembrolizumab monotherapy in patients with non-small-cell lung cancer.